IP Library › Granted Patent US 11,104,905
Granted Patent B2
US 11,104,905 · App. 16/991,635 · Granted Aug 31, 2021

Aptamers against

Inventors: Ronald J. Shannon (Malvern, PA); Michael McIntyre (Malvern, PA); David Bunka (York, GB); Edward Barnes (York, GB)
Assignee: Biovector, Inc.
C12N15/115C12Q1/689C12N2310/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,104,905
App. No.
16/991,635
Filed
Aug 12, 2020
Granted
Aug 31, 2021
Kind
B2
Examiner
SHIN, DANA H
Art Unit
1635
USPC
435/6.15
Abstract

Compositions comprising aptamers capable of specifically binding to a surface protein of Clostridium difficile spore are provided. A method for detecting, enriching, separating, and/or isolating Clostridium difficile spores is provided.

Claims (15)

1. An aptamer having a specific binding affinity for a surface protein of Clostridium difficile spore, wherein the aptamer comprises a nucleic acid sequence having at least 90% identity with SEQ ID NO: 11, and wherein the surface protein is CotE.

2. The aptamer of claim 1 , wherein the surface protein CotE comprises an amino acid sequence as set forth in SEQ ID NO: 16.

3. The aptamer of claim 1 , wherein the aptamer comprises a detectable label.

4. The aptamer of claim 3 , wherein the detectable label comprises a fluorophore.

5. The aptamer of claim 4 , wherein the fluorophore comprises a quantum dot.

6. An apparatus for detecting the presence, absence or level of Clostridium difficile spores in a sample, the apparatus comprising:

a support; and

an aptamer having a specific binding affinity for a surface protein of Clostridium difficile spore, wherein the aptamer comprises a nucleic acid sequence having at least 90% identity with SEQ ID NO: 11 having a binding affinity to CotE.

7. The apparatus of claim 6 , wherein the aptamer comprises a detectable label.

8. The apparatus of claim 7 , wherein the detectable label comprises a fluorophore.

9. The apparatus of claim 8 , wherein the fluorophore comprises a quantum dot.

10. A composition comprising an aptamer having a specific binding affinity for a surface protein of Clostridium difficile spore, wherein the aptamer comprises a nucleic acid sequence having at least 90% identity with SEQ ID NO: 11 having a binding affinity to CotE.

11. The composition of claim 10 , wherein the aptamer comprises a detectable label.

12. The composition of claim 11 , wherein the detectable label comprises a fluorophore.

13. The composition of claim 12 , wherein the fluorophore comprises a quantum dot.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2021
From: BIOVECTOR, INC.
To: LIV PROCESS, INC.
Reel/Frame 058796/0180 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2020
From: SHANNON, RONALD J.; MCINTYRE, MICHAEL; BUNKA, DAVID; BARNES, EDWARD
To: BIOVECTOR, INC.
Reel/Frame 053899/0372 →
Continuity (4)
Division 16893935 · Jun 5, 2020
Provisional Application 62857639 · Jun 5, 2019
Provisional Application 62983095 · Feb 28, 2020
Related Publication 20200385731A1 · Dec 10, 2020
Cited By (2)
US 12,338,442 US 12,708,119